Holen Sie sich die Stockscreener-App
1.85
2.56%
-0.10
Veraxa Biotech Ag Aktie (VRXA) Neueste Nachrichten
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026) - Stock Titan
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform - citybuzz -
Veraxa Biotech Holding AG SEC Filing (Aug 7, 2026) - Stock Titan
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - Benzinga
VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio - citybuzz.co
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA Today
Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock Titan
Veraxa Biotech files first BiTAC patent applications in 2026 By Investing.com - Investing.com Canada
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates - The Manila Times
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures - Benzinga
Veraxa Biotech AG Ord Shs (VRXA) Institutional Confidence - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire
Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com South Africa
Veraxa Biotech AG Ord Shs (VRXA) Cash Flow - TradingKey
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -
Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Income Statement - TradingKey
Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire
Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn
VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio - The Manila Times
Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK
VERAXA Biotech AG Appoints Christoph Erkel, Ph.D., as Chief Scientific Officer - Quiver Quantitative
VERAXA Taps 20-Year Antibody Expert to Guide New Cancer Treatments - Stock Titan
VERAXA Biotech Receives Positive Regulatory Guidance for BiTAC-TCE Platform from German Authority - citybuzz -
VERAXA Biotech (NASDAQ: VRXA) Initiates Cell Line Development for Lead BiTAC Cancer Therapy Program - USA Today
Oliver Rolf Baumann Net Worth (2026) - GuruFocus
1.34%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):